Sirolimus Eluting Stent is indicated for improving luminal diameter and reducing restenosis for treatment of coronary artery lesions in native coronary arteries. This stent is also indicated for intraluminal chronic placement in stenosed coronary artery or aorto-coronary bypass grafts in order to obtain vessel patency following acute or subacute coronary artery obstruction. It is also indicated for restenosis or arterial dissection after PTCA procedure. Patients being considered for stent implantation should be acceptable candidates for coronary balloon angioplasty.
Drug-eluting stent product coats with Rapamycin (Sirolimus), the biodegradable component polylactide (PLA), which has an excellent history of pre-clinical and long-term clinical results.
- A CoCr Stent – designed for all lesions
- Unique stent surface
- Low stent profile
- The suitable catheter